TITLE

Efficacy of Short-Term Growth Hormone Treatment in Prepubertal Children with Idiopathic Short Stature

AUTHOR(S)
Ho-Seong Kim; Sei Won Yang; Han-Wook Yoo; Byung Kyu Suh; Cheol Woo Ko; Woo Yeong Chung; Kee Hyoung Lee; Jin Soon Hwang; Hyi-Jeong Ji; Hyunji Ahn; Duk Hee Kim
PUB. DATE
January 2014
SOURCE
Yonsei Medical Journal;Jan2014, Vol. 55 Issue 1, p53
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: It has been reported that daily recombinant human growth hormone (GH) treatment showed beneficial effects on growth in prepubertal children with idiopathic short stature (ISS). The present study aimed to validate the GH (Eutropin®) effect on growth promotion and safety after short-term GH treatment. Materials and Methods: This study was an open-label, multicenter, interventional study conducted at nine university hospitals in Korea between 2008 and 2009. Thirty six prepubertal children with ISS were enrolled in this study to receive 6-month GH treatment. Yearly growth rate, height standard deviation score (SDS), and adverse events were investigated during treatment. Results: After 26 weeks of GH treatment, the height velocity significantly increased by 6.36±3.36 cm/year (p<0.001). The lower end of one-sided 95% confidence interval was 5.22 cm/year, far greater than the predefined effect size. The gain in height SDS at week 26 was 0.57±0.27 (p<0.0001). Bone age significantly increased after GH treatment, however, bone maturation rate (bone age for chronological age) showed limited advancement. This 26-week GH treatment was effective in increasing serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 from baseline (p<0.0001). Eutropin was well tolerated and there were no withdrawals due to adverse events. No clinically significant changes in laboratory values were observed. Conclusion: This 6-month daily GH treatment in children with ISS demonstrated increased height velocity, improved height SDS, and increased IGF-I and IGFBP-3 levels with a favorable safety profile.
ACCESSION #
93368044

 

Related Articles

  • Effects of Recombinant Human Growth Hormone on Fat Distribution in Patients with Human Immunodeficiency Virus--Associated Wasting. Tai, Viva W.; Schambelan, Morris; Algren, Heather; Shayevich, Clara; Mulligan, Kathleen // Clinical Infectious Diseases;11/15/2002, Vol. 35 Issue 10, p1258 

    In light of current interest in recombinant human growth hormone (GH) as a treatment for fat distribution abnormalities, we retrospectively evaluated regional changes in fat and lean body mass in a subset of subjects who participated in randomized, double-blind, placebo-controlled trials of GH...

  • Erratum to: Prokaryotic expression, purification and functional characterization of recombinant human RIP2. Cai, Xin; Wang, Min; Kong, Haibo; Liu, Jing; Liu, Ye; Xia, Wengrong; Zou, Minji; Wang, Jiaxi; Su, Hang; Xu, Donggang // Molecular Biology Reports;Jan2013, Vol. 40 Issue 1, p737 

    A correction to the article "Prokaryotic Expression, Purification and Functional Characterization of Recombinant Human RIP2," by Xin Cai and colleagues, published in previous issue, is presented.

  • RhGH May Aggravate Tendency to Disproportionate Growth.  // Kidney;Jul/Aug98, Vol. 7 Issue 4, p177 

    Presents a summary of the article 'X-Linked Hypophosphatemia: Effects of Treatment With Recombinant Human Growth Hormone,' by G.S. Reusz, G. Mitenyi et al published in 'Pediatric Nephrology' periodical.

  • Renin Inhibits N-Acetyl-d-Glucosamine 2-Epimerase (Renin-Binding Protein)1. Takahashi, Saori; Kumagai, Masanori; Shindo, Sho; Saito, Kyuichi; Kawamura, Yukio // Journal of Biochemistry;2000, Vol. 128 Issue 6, p951 

    Renin-binding protein (RnBP) is a highly specific renin inhibitor first isolated from porcine kidney. Our recent studies demonstrated that the human RnBP is the enzyme N-acetyl-d-glucosamine (GlcNAc) 2-epimerase [Takahashi, S. et al. (1999) J. Biochem. 125, 348–353]. We have developed a...

  • Twice-daily IGF-I increased first-year height velocity in prepubertal children. Brannon, Matthew // Endocrine Today;Mar2010, Vol. 8 Issue 3, p24 

    The article reports on the age- and dose-dependent increases in first-year height velocity and height standard deviation scores in prepubertal children with short stature, low insulin-like growth factor I (IGF-I) and normal growth hormone levels and who are assigned to twice-daily recombinant...

  • Growth hormone therapy in chronic renal failure induces catch-up of head circumference. Van Dyck, Maria; Proesmans, W. // Pediatric Nephrology;Aug2001, Vol. 16 Issue 8, p631 

    Growth of head circumference was studied along with height, weight, and body mass index (BMI) in 21 prepubertal patients with chronic renal failure (CRF) before and during recombinant human growth hormone (rhGH) treatment. CRF was present from birth in 15 patients, in the 6 others it was...

  • CITATIONS AND CLINICIANS' NOTES: CYSTIC FIBROSIS.  // Current Medical Literature: Respiratory Medicine;2004, Vol. 18 Issue 2, p49 

    Presents the abstract for the article "Prospective Randomised Treatment With Recombinant Human Growth Hormone in Cystic Fibrosis," by A. Schibler, R. von der Heiden, P. Birrer, and P. E. Mullis.

  • Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Matorras, R.; Prieto, B.; Exposito, A.; Mendoza, R.; Crisol, L.; Herranz, P.; Burgu�s, S. // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Feb2011 Supplement, Vol. 22 Issue S1, p879 

    This single-centre, randomized, parallel group, comparative study aimed to identify potential benefits of mid-follicular recombinant human LH (r-HLH) supplementation in women aged 35-39 years undergoing ovarian stimulation for intracytoplasmic sperm injection (ICSI). The main endpoint was the...

  • Kinetics of Inclusion Body Formation and Its Correlation with the Characteristics of Protein Aggregates in Escherichia coli. Upadhyay, Arun K.; Murmu, Aruna; Singh, Anupam; Panda, Amulya K. // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    The objective of the research was to understand the structural determinants governing protein aggregation into inclusion bodies during expression of recombinant proteins in Escherichia coli. Recombinant human growth hormone (hGH) and asparaginase were expressed as inclusion bodies in E.coli and...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics